Key takeaways for Wyoming
- • Zepbound is the FIRST and ONLY FDA-approved drug for OSA (Dec 2024).
- • Approved only for moderate-to-severe OSA in adults with obesity.
- • AHI reductions of 25-30 events/hour in the SURMOUNT-OSA trials.
- • Wyoming Medicaid coverage rules apply for Obstructive Sleep Apnea patients in Wyoming — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Obstructive Sleep Apnea
Zepbound is FDA-approved (Dec 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity. Evidence grade: A. In the SURMOUNT-OSA trials, tirzepatide reduced the apnea-hypopnea index (AHI) by roughly 25-30 events per hour at 52 weeks, with a substantial fraction of patients reaching disease remission. CPAP remains standard of care — Zepbound is positioned as adjunct or alternative for patients who cannot tolerate CPAP. Other GLP-1s (Wegovy, semaglutide) are not approved for OSA but may produce indirect benefit via weight loss.
Wyoming-specific context
Wyoming has telehealth access concentrated in Cheyenne, Casper, Laramie metros, with additional reach to Gillette and Rock Springs. Wyoming Medical Center, Cheyenne Regional Medical Center is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at health.wyo.gov.
Wyomingtelehealth & pricing rules
- • Wyoming permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Wyoming allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Wyoming: ~$251/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.